JLB & Associates is an investment advisory firm founded in 1983 and has a current portfolio of $278 million, as per its recent SEC 13F filing on October 7, 2014. Gilead Sciences, Inc. (NASDAQ:GILD), Mastercard Inc (NYSE:MA), Oracle Corporation (NYSE:ORCL) are among the top three stock holdings of the company. Information technology is the largest investment area of the fund followed by health care industry.
Gilead Sciences, Inc. (NASDAQ:GILD) is the primary investment of JLB & Associates with 110,470 shares and investment worth $11.7 million. It is an excellent period for the biopharmaceutical company as the FDA approved its Chronic Hepatitis C medicine. Its Hepatitis C drug, Harvoni, had positive results in nearly 94% to 96% cases in the three phase studies conducted during its phase three trials. Gilead Sciences, Inc. (NASDAQ:GILD) is likely to charge up to $1,000 for every single pill and it offers a 12-week program against the disease. Its top three hedge fund investors include Egerton Capital Limited, Orbis Investment Management, and Columbus Circle Investors.
JLB & Associates Inc has investments worth $9.1 million in Mastercard Inc (NYSE:MA) with 124,185 shares of the company. Earlier this month, Mastercard Inc (NYSE:MA) struck a deal with Costco Wholesale Corporation (NASDAQ:COST) to offer a co-branded credit card to the retailer’s Canadian customers, as Costco ends its arrangement with American Express Company (NYSE:AXP) this year. Some of the top investors in Mastercard Inc (NYSE:MA) include Lone Pine Capital, Gardner Russo & Gardener, and Viking Global.
Oracle Corporation (NYSE:ORCL) comes number three in JLB & Associates portfolio with investments worth $8.8 million and 231,716 shares of the company. Oracle Corporation (NYSE:ORCL) is close to acquiring Concur Technologies for $8.3 billion and the company has closed several deals in the past few months including its acquisition of Front Porch Digital and MICROS Systems in September alone. Eagle Capital Management is the largest investor of Oracle Corporation (NYSE:ORCL) and First Eagle Investment Management and Yacktman Asset Management follow Eagle in their respective investments.
This article has been written and edited by Prakash Pandey
Gilead Sciences, Inc. (GILD) Wins FDA Approval for Hepatitis C Drug That Costs More Than $1000 a Pill
Gilead Sciences, Inc. (GILD) Says Pancreatic Cancer Treatment, Simtuzumab, Failed to Meet Trial Goals in Phase II
Read: Warren Buffett and Billionaires Are Crazy About These 7 Stocks